180 related articles for article (PubMed ID: 32744884)
1.
Prasun P
J Interferon Cytokine Res; 2020 Sep; 40(9):466-467. PubMed ID: 32744884
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
Amor S; Baker D; Khoury SJ; Schmierer K; Giovanonni G
Ann Neurol; 2020 Jun; 87(6):794-797. PubMed ID: 32383812
[No Abstract] [Full Text] [Related]
3. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
4. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2.
Luan J; Lu Y; Gao S; Zhang L
J Infect; 2020 Aug; 81(2):318-356. PubMed ID: 32283163
[No Abstract] [Full Text] [Related]
5. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine therapy during the COVID-19 pandemic.
Rudnicka L; Glowacka P; Goldust M; Sikora M; Sar-Pomian M; Rakowska A; Samochocki Z; Olszewska M
J Am Acad Dermatol; 2020 Aug; 83(2):e151-e152. PubMed ID: 32376422
[No Abstract] [Full Text] [Related]
7. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
Yu C; Kang L; Chen J; Zang N
Int Immunopharmacol; 2020 Sep; 86():106740. PubMed ID: 32645630
[TBL] [Abstract][Full Text] [Related]
8. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
[TBL] [Abstract][Full Text] [Related]
9. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
10. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
11. The role of IgG Fc receptors in antibody-dependent enhancement.
Bournazos S; Gupta A; Ravetch JV
Nat Rev Immunol; 2020 Oct; 20(10):633-643. PubMed ID: 32782358
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of type I interferon responses in COVID-19.
Acharya D; Liu G; Gack MU
Nat Rev Immunol; 2020 Jul; 20(7):397-398. PubMed ID: 32457522
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
14. A comparative overview of COVID-19, MERS and SARS: Review article.
Liu J; Xie W; Wang Y; Xiong Y; Chen S; Han J; Wu Q
Int J Surg; 2020 Sep; 81():1-8. PubMed ID: 32730205
[TBL] [Abstract][Full Text] [Related]
15. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
16. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
17. Should we unstress SARS-CoV-2 infected cells?
Csukasi F; Rico G; Becerra J; Duran I
Cytokine Growth Factor Rev; 2020 Aug; 54():3-5. PubMed ID: 32563554
[No Abstract] [Full Text] [Related]
18. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.
Wang Y; Wang Y; Chen Y; Qin Q
J Med Virol; 2020 Jun; 92(6):568-576. PubMed ID: 32134116
[TBL] [Abstract][Full Text] [Related]
19. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
Costiniuk CT; Jenabian MA
Cytokine Growth Factor Rev; 2020 Jun; 53():63-65. PubMed ID: 32467020
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
Rat P; Olivier E; Dutot M
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7880-7885. PubMed ID: 32744716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
